NEW YORK (
CHANGE IN RATINGS
Advance Auto Parts
upgraded at UBS to Buy from Neutral, UBS said. $90 price target. Company is poised for more consistent execution.
downgraded at Morgan Stanley from Overweight to Equal-weight, Morgan Stanley said. Valuation call, based on a $14 price target.
( APKT)rated new Equal-weight at Morgan Stanley. SBC market growth should continue to slow in 2012.
upgraded to buy at TheStreet Ratings
upgraded at Goldman from Sell to Neutral, Goldman Sachs said. $370 price target. Commercial rollout is gaining traction.
Bank of America
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Company needs to cut costs and faces high execution risks.
rated new Hold at Kaufman. $6 price target. Company faces sales headwinds in the first half of the year.
upgraded to buy at TheStreet Ratings.
upgraded at Goldman to Buy from Neutral, Goldman Sachs said. Company has a clear path to return capital.
downgraded at Dahlman from Buy to Hold, Dahlman Rose said. Valuation call, based on a $180 price target.
downgraded at Goldman from Neutral to Sell, Goldman Sachs said. Valuation call, based on a $46 price target. End-market demand appears to be peaking.
downgraded at KBW to Market Perform, Keefe, Bruyette & Woods said. Valuation call, based on a $15 price target.
Hain Celestial Group
added to Top Picks Live at Citigroup. $46 price target. Well positioned for solid growth in 2012.
downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. $48 price target. Earnings will likely disappoint over the next couple of years.
upgraded at Goldman from Neutral to Buy, Goldman Sachs said. End-market demand is bottoming and the company can deliver accelerated earnings growth. $17 price target.
upgraded at KBW from Market Perform to Outperform, Keefe, Bruyette & Woods said. $31 price target. Flow trends are improving.
upgraded at Goldman from Neutral to Buy, Goldman Sachs said. Company was also placed on the Conviction List. $23 price target. Company is focused on fixing legacy issues.
Procter & Gamble
downgraded at UBS to Neutral from Buy, UBS said. $66 price target. Incremental risk to downwardly revised guidance.
upgraded at JMP from Market Perform to Outperform, JMP Securities said. $27 price target. Stock is pricing in near-term risks.
rated new Buy at Kaufman. $21 price target. Company is leveraged to continued growth in cloud computing and demand should accelerate in the second half of the year.
upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $105 price target. Survey suggests rapid Eylea adoption.
rated new Buy at Deutsche. $24 price target. Company is consistently profitable, with industry-leading returns.
downgraded at Goldman to Sell, Goldman Sachs said. Company should underperform other hardlines names.
upgraded at Wells to Outperform, Wells Fargo said. Investor sentiment and expectations are too low.
upgraded at Piper from Neutral to Overweight, Piper Jaffray said. $75 price target. Orthopedic market should improve throughout 2012.
STOCK COMMENTS / EPS CHANGES
( AMLN) estimates, target raised at Goldman. Shares of AMLN now seen reaching $11, according to Goldman Sachs. Estimates also increased, on the Bydureon FDA approval. Sell rating.
estimates lowered at UBS through 2012, UBS said. Nokia Symbian weakness. Maintain Buy rating and $45 price target.
numbers cut at Morgan Stanley. Shares of CRR now seen reaching $150, according to Morgan Stanley. Estimates also reduced, as the company faces logistical challenges. Underweight rating.
numbers boosted at Baird. Shares of CSCO now seen reaching $21, according to Robert Baird. Estimates also upped, following a positive reseller survey. Neutral rating.
estimates reduced at Credit Suisse through 2014, Credit Suisse said. Company is seeing lower volumes. Outperform rating and $130 price target.
numbers boosted at Guggenheim. Shares of DHI now seen reaching $14, according to Guggenheim. Estimates also upped, as the company is realizing higher margins. Neutral rating.
estimates, target lowered at UBS.Shares of F now seen reaching $15, according to UBS. Estimates also lowered after 4Q miss driven by commodity and fx costs. Buy rating.
Ford Motor estimates lowered at Sterne Agee. F estimates were cut through 2013, Sterne Agee said. Company is seeing slower growth in Europe and lower finance profits. Buy rating and $18 price target.
estimates, target raised at Morgan Stanley.Shares of HON now seen reaching $64, according to Morgan Stanley. Estimates also increased, as the company continues to execute well. Overweight rating.
numbers raised at Credit Suisse. Shares of JBHT now seen reaching $56, according to Credit Suisse. Estimates also increased, as the company is seeing better intermodal volumes. Neutral rating.
cut from Conviction Buy List at Goldman. Company has limited earnings upside potential.
estimates, target upped at Keybanc.KMT estimates were raised through 2013, Keybanc said. Recent acquisition should add to earnings. Buy rating and new $50 price target.
numbers boosted at Morgan Stanley. Shares of LM now seen reaching $30, according to Morgan Stanley. Estimates also upped, as the company is cutting costs. Equal-weight rating.
estimates lowered at UBS through 2013, UBS said. Storage recovery delays and year end wireless softness. Buy rating and $18 price target.
numbers increased at Morgan Stanley. NWL estimates were raised through 2013, Morgan Stanley said. Company has strong visibility. Overweight rating and new $22 price target.
Procter & Gamble
numbers cut at Credit Suisse. PG estimates were reduced through 2014, Credit Suisse said. Company is being hurt by a stronger dollar. Outperform rating and $70 price target.
numbers reduced at Goldman.Shares of RCL now seen reaching $29, according to Goldman Sachs. Estimates also cut, given lower expected net yields. Neutral rating.
estimates, target increased at Keybanc. TKR estimates were raised through 2013, Keybanc said. Company is seeing solid growth across the board. Buy rating and new $64 price target.
numbers upped at JP Morgan. UPS estimates were boosted through 2013, JP Morgan said. Company is seeing lower pension costs. Neutral rating and new $86 price target.
cut from Conviction Buy List at Goldman. WFM was removed from the Conviction Buy list, Goldman Sachs said. Valuation call, as the stock is up 44% over the past year, versus a flat market. New $84 price target.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of TheStreet.